Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

Worm study links gut bacteria to alpha-synuclein clumping

Bacteria in the group Desulfovibrio may promote the disease-driving clumping of alpha-synuclein protein in Parkinson’s disease, a new study done in nematode worms suggests. “Our findings make it possible to screen for the carriers of these harmful Desulfovibrio bacteria. Consequently, they can be targeted by measures to remove these strains…

Vaxxinity shares update about potential vaccine UB-312

Results from a Phase 1 clinical trial testing the experimental vaccine UB-312 in people with Parkinson’s disease are expected this summer, according to the therapy’s developer Vaxxinity. “Vaxxinity remains on track to meet critical milestones in 2023,” Mei Mei Hu, the company’s CEO, said in a press…

Novel machine learning tool IDs early Parkinson’s biomarkers

A novel machine learning tool, called CRANK-MS, was able to identify, with high accuracy, people who would go on to develop Parkinson’s disease, based on an analysis of blood molecules. The algorithm identified several molecules that may serve as early biomarkers of Parkinson’s. These findings show the potential of…

PharmaTher seeks fast-track status for ketamine

PharmaTher Holdings has applied to the U.S. Food and Drug Administration (FDA) asking that ketamine be given fast-track designation as a potential treatment for dyskinesia, or uncontrolled movements, that occur as a side effect of levodopa being used by people with Parkinson’s disease. The fast-track designation is designed…